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Abstract
The food enzyme is an a-amylase (4-a-D-glucan glucanohydrolase; EC 3.2.1.1) produced with a
genetically modified Bacillus licheniformis strain NZYM-AN by Novozymes A/S. The genetic
modifications do not give rise to safety concerns. The food enzyme does not contain the production
organism or recombinant DNA; therefore, there is no safety concern for the environment. The
a-amylase is intended to be used in starch processing for the production of glucose syrups and distilled
alcohol production. Residual amounts of total organic solids (TOS) are removed by distillation and by
the purification steps applied during the production of glucose syrups (by > 99%). Consequently,
dietary exposure was not calculated. Genotoxicity tests with the food enzyme did not raise a safety
concern. The amino acid sequence of the food enzyme did not match to those of known allergens. The
Panel considered that under the intended condition of use, the risk of allergic sensitisation and
elicitation reactions upon dietary exposure to this food enzyme cannot be excluded, but the likelihood
is considered low. Based on the microbial source, the genetic modifications, the manufacturing
process, the compositional and biochemical data, the removal of TOS during the intended food
production processes and the findings in the genotoxicity studies, the Panel concluded that this food
enzyme does not give rise to safety concerns under the intended conditions of use.
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1. Introduction
Article 3 of the Regulation (EC) No 1332/20081 provides definitions for ‘food enzyme’ and ‘food
enzyme preparation’.
‘Food enzyme’ means a product obtained from plants, animals or micro-organisms or products
thereof including a product obtained by a fermentation process using micro-organisms: (i) containing
one or more enzymes capable of catalysing a specific biochemical reaction; and (ii) added to food for a
technological purpose at any stage of the manufacturing, processing, preparation, treatment,
packaging, transport or storage of foods.
‘Food enzyme preparation’ means a formulation consisting of one or more food enzymes in which
substances such as food additives and/or other food ingredients are incorporated to facilitate their
storage, sale, standardisation, dilution or dissolution.
Before January 2009, food enzymes other than those used as food additives were not regulated or
were regulated as processing aids under the legislation of the Member States. On 20 January 2009,
Regulation (EC) No 1332/2008 on food enzymes came into force. This Regulation applies to enzymes
that are added to food to perform a technological function in the manufacture, processing,
preparation, treatment, packaging, transport or storage of such food, including enzymes used as
processing aids. Regulation (EC) No 1331/20082 established the European Union (EU) procedures for
the safety assessment and the authorisation procedure of food additives, food enzymes and food
flavourings. The use of a food enzyme shall be authorised only if it is demonstrated that:
1) it does not pose a safety concern to the health of the consumer at the level of use proposed,
2) there is a reasonable technological need, and
3) its use does not mislead the consumer.
All food enzymes currently on the EU market and intended to remain on that market as well as all
new food enzymes shall be subjected to a safety evaluation by the European Food Safety Authority
(EFSA) and approval via an EU Community list.
The ‘Guidance on submission of a dossier on food enzymes for safety evaluation’ (EFSA CEF Panel,
2009) lays down the administrative, technical and toxicological data required.
1.1. Background and Terms of Reference as provided by the requestor
1.1.1. Background as provided by the European Commission
Only food enzymes included in the Union list may be placed on the market as such and used in
foods, in accordance with the specifications and conditions of use provided for in Article 7 (2) of
Regulation (EC) No 1332/2008 on food enzymes.
Five applications have been introduced by the companies ‘Roquette’, ‘Novozymes A/S’, ‘DSM Food
Specialities B.V.’ and ‘Advanced Enzyme Technologies Ltd.’ For the authorisation of the food enzymes
Beta-amylase from wheat (Triticum spp), Alpha-amylase from a genetically modified strain of
Bacillus licheniformis (strain NZYM-AN), Chymosin from a genetically modified strain of Kluyveromyces
lactis (strain CIN), Polygalacturonase from a genetically modified strain of Aspergillus niger (strain
FLYSC) and Pectinestrerase from a genetically modified strain of Aspergillus niger (strain FLZSC).
Following the requirements of Article 12.1 of Commission Regulation (EU) No 234/20113
implementing Regulation (EC) No 1331/20082, the Commission has verified that the five applications
fall within the scope of the food enzyme Regulation and contain all the elements required under
Chapter II of that Regulation.
1.1.2. Terms of Reference
The European Commission requests the European Food Safety Authority to carry out a safety
assessments of the food enzymes Beta-amylase from wheat (Triticum spp), Alpha-amylase from a
1 Regulation (EC) No 1332/2008 of the European Parliament and of the Council of 16 December 2008 on Food Enzymes and
Amending Council Directive 83/417/EEC, Council Regulation (EC) No 1493/1999, Directive 2000/13/EC, Council Directive 2001/
112/EC and Regulation (EC) No 258/97. OJ L 354, 31.12.2008, p. 7–15.
2 Regulation (EC) No 1331/2008 of the European Parliament and of the Council of 16 December 2008 establishing a common
authorisation procedure for food additives, food enzymes and food flavourings. OJ L 354, 31.12.2008, p. 1–6.
3 Commission Regulation (EU) No 234/2011 of 10 March 2011 implementing Regulation (EC) No 1331/2008 of the European
Parliament and of the Council establishing a common authorisation procedure for food additives, food enzymes and food
flavourings. OJ L 64, 11.3.2011, p. 15–24.
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genetically modified strain of Bacillus licheniformis (strain NZYM-AN), Chymosin from a genetically
modified strain of Kluyveromyces lactis (strain CIN), Polygalacturonase from a genetically modified
strain of Aspergillus niger (strain FLYSC) and Pectinestrerase from a genetically modified strain of
Aspergillus niger (strain FLZSC) in accordance with Article 17.3 of Regulation (EC) No 1332/2008 on
food enzymes.
1.2. Interpretation of Terms of Reference
The present scientific opinion addresses the European Commission request to carry out of the
safety assessment of the food enzyme alpha-amylase from a genetically modified strain of
Bacillus licheniformis (strain NZYM-AN).
1.3. Information on existing authorisations and evaluations
The applicant reports that the authorities of France and Denmark have evaluated and authorised
the use of a-amylase produced by genetically modified strains of Bacillus licheniformis in a number of
food and beverage manufacturing processes (i.e. beverage alcohol production, starch processing,
brewing processes) and specified the conditions of use.
2. Data and methodologies
2.1. Data
The applicant has submitted a dossier in support of the application for authorisation of the food
enzyme a-amylase from a genetically modified Bacillus licheniformis (strain NZYM-AN). The food
enzyme is intended to be used in two food-manufacturing processes: starch processing for the
production of glucose syrups as well as in distilled alcohol production.
2.2. Methodologies
The assessment was conducted in line with the principles described in the EFSA ‘Guidance on
transparency in the scientific aspects of risk assessment’ (EFSA, 2009) and following the relevant
existing guidances from the EFSA Scientific Committee.
The current ‘Guidance on submission of a dossier on food enzymes for safety evaluation’ (EFSA CEF
Panel, 2009) has been followed for the evaluation of the application with the exception of the
exposure assessment, which was carried out in accordance with the methodology described in the CEF
Panel statement on the exposure assessment of food enzymes (EFSA CEF Panel, 2016).
3. Assessment
3.1. Technical data
3.1.1. Identity of the food enzyme
IUBMB nomenclature: a-amylase
Systematic name: 4-a-D-glucan glucanohydrolase
Synonyms: glycogenase, 1,4-a-D-glucan glucanohydrolase




The molecular mass of 55.2 kDa reported in the dossier for the a-amylase produced by
Bacillus licheniformis (strain NZYM-AN) was calculated from the amino acid sequence and was
confirmed by sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE). The SDS-PAGE
gel consistently showed a single major protein band in all batches.
Other enzymes (glucoamylase, lipase and protease) were analysed in three commercial food
enzyme batches and were below the limits of detection of the applied assays.
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Data on chemical parameters of the food enzyme have been provided for three commercial batches
and two batches used for the toxicological tests (Table 1). The average total organic solids (TOS)
content of the three commercial batches was 8.7% (w/w); the values ranged from 8.0% to 10.0%
(Table 1). The TOS content is a calculated value derived as 100% minus % water minus % ash. The
five food enzyme batches presented in Table 1 are concentrates without any added diluents.
The enzyme activity/TOS ratio of the three commercial food enzyme batches ranged from 12.2 to
14.1 KNU(T)/mg TOS (Table 1). The average value of 13.2 KNU(T)/mg TOS was used for subsequent
calculations.
The food enzyme complies with the specification for lead (not more than 5 mg/kg) as laid down in
the general specifications and considerations for enzymes used in food processing (FAO/WHO, 2006).
In addition, the levels of arsenic, cadmium and mercury were below the respective limits of detection
of the employed methodologies.4
No antimicrobial activity was detected in any of these batches (FAO/WHO 2006).
The food enzyme complies with the microbiological criteria as laid down in the general
specifications and considerations for enzymes used in food processing (FAO/WHO, 2006), which
stipulate that Escherichia coli and Salmonella species are absent in 25 g of sample, and total coliforms
are present at not more than 30 colony-forming units per gram.
The applicant has provided information on the identity of the antifoam agents used. Taking into
account the nature and properties of the antifoam agents, the manufacturing process and the quality
assurance system implemented by the applicant, the Panel considers their use as of no safety concern.
The Panel considered the compositional data provided for the food enzyme as sufficient.
3.1.3. Properties of the food enzyme
The a-amylase catalyses the hydrolysis of a–1,4-glycosidic linkages in starch (amylose and
amylopectin), glycogen and related polysaccharides and oligosaccharides, resulting in the generation of
soluble dextrins and other oligosaccharides.
The a-amylase activity is quantified by a method based on the hydrolysis of a synthetic substrate
(4,6-ethylidene(G7)-p-nitrophenyl(G1)-alpha-D-maltoheptaoside (ethylidene-G7pNP)) to glucose and
the yellow-coloured p-nitrophenol which is determined spectrophotometrically at 405 nm (reaction
conditions: 37°C, pH 7.0). The activity is measured relative to an internal enzyme standard, and the
result is given in Kilo Novo alpha-amylase Units (T standard)/g (KNU(T)/g).
The temperature/activity profile of the food enzyme was measured from 30°C up to 90°C at pH 4.5
which showed that the a-amylase is active at temperatures up to 85°C with an optimum at 80°C. The
pH profile was measured within a pH range from 2.0 to 10.0 at 30°C. The a-amylase is active at pH
conditions up to 9.5, with an optimum at pH 7. The a-amylase stability decreases rapidly above 60°C
showing no residual activity at 80°C.
Table 1: Compositional data provided for the food enzyme
Parameter Unit
Batch
1 2 3 4(a) 5(b)
a-Amylase activity KNU(T)/g(c) 976 1,340 1,130 913 1,090
Protein % 7.2 9.4 7.7 NA NA
Ash % 1.2 1.6 1.7 1.6 2.6
Water % 90.8 88.4 90.3 90.0 86.0
Total organic solids (TOS)(d) % 8.0 10.0 8.0 8.4 11.4
a-amylase activity/mg TOS KNU(T)/mg TOS 12.2 13.4 14.1 10.9 9.6
(a): Batch used for the genotoxicity tests (Ames and micronucleus).
(b): Batch used for the systemic 90-day oral toxicity study.
(c): KNU(T): Kilo Novo alpha-amylase Units (T standard)/g (see Section 3.1.3).
(d): TOS calculated as 100% - % water - % ash.
4 Limit of detection (LOD): Pb: 0.5 mg/kg; As: 0.3 mg/kg; Cd and Hg: 0.5 mg/kg.
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3.1.4. Information on the source material
3.1.4.1. Information on the genetically modified microorganism
The a–amylase is produced with the genetically modified production strain B. licheniformis NZYM-AN,
which is deposited in the
with the deposit number .
3.1.4.2. Characteristics of the parental and recipient microorganisms
The parental microorganism is the bacterium B. licheniformis strain . B. licheniformis is
recommended for the Qualified Presumption of Safety (QPS) status, with the qualification that the
absence of acquired antimicrobial resistance genes and toxigenic activity are verified for the specific
strain used (EFSA BIOHAZ Panel, 2017a,b).
The parental strain was identified as B. licheniformis by
. The strain shows no cytotoxic activity in Chinese hamster ovary cells (Pedersen et al., 2002)
and VERO cells. The absence of cytotoxicity has also been shown by the same methodology in strain
, an intermediate strain obtained
(Pedersen et al., 2002).
The recipient strain B. licheniformis was derived from
3.1.4.3. Characteristics of the introduced sequences
3.1.4.4. Description of the genetic modification process
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3.1.4.5. Safety aspects of the production strain
The production strain B. licheniformis NZYM-AN differs from the parental strain
The stability of the genetic modification was demonstrated by
Bacillus licheniformis is recommended for the QPS status, with the qualification that the absence of
acquired antimicrobial resistance genes and toxigenic activity are verified for the specific strain used
(EFSA BIOHAZ Panel, 2017a,b). The parental strain B. licheniformis strain and an intermediate
strain obtained were shown not to
be cytotoxic. The absence of acquired antibiotic resistance has not been shown for the production
strain, however taking into account the absence of production organism and DNA in the final product
(see Section 3.1.5), the Panel did not consider this to be necessary. None of the introduced traits
raises safety concerns and therefore the production strain can be presumed to be of no concern.
3.1.5. Manufacturing process
The food enzyme is manufactured according to the Food Hygiene Regulation (EC) No 852/20045,
with food safety procedures based on Hazard Analysis and Critical Control Points (HACCP), and in
accordance with Good Manufacturing Practice (GMP).
The food enzyme is produced by a pure culture in a contained, , fermentation
system with conventional process controls in place. The identity and purity of the culture are checked
at each transfer step from frozen vials until the end of fermentation.
The food enzyme produced is recovered from the fermentation broth after biomass separation
using filtration. Further purification and concentration involve a series of filtration steps, including
and . The food enzyme is then formulated as a solid or liquid product.
The absence of the production strain in the product was demonstrated in
5 Regulation (EC) No 852/2004 of the European Parliament and of the Council of 29 April 2004 on the hygiene of food additives.
OJ L 226, 25.6.2004, p. 3–21.
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No DNA was found in
The Panel considered the information provided on the raw materials and the manufacturing process
as sufficient.
3.1.6. Safety for the environment
The production strain and its DNA were not detected in the final product. Therefore, the
Panel concluded that there is no safety concern for the environment.
3.1.7. Case of need and intended conditions of use
The food enzyme is intended to be used for distilled alcohol production and in starch processing for
the production of glucose syrups. The maximum recommended use level of the food enzyme as
provided by the applicant is 300 KNU(T)/kg starch dry matter, corresponding to 22.7 mg TOS/kg
starch dry matter.
In distilled alcohol production, the food enzyme is added before the slurry mixing step and in the
liquefaction step. a-Amylase is intended to be used to convert liquefied starch into a maltose-rich
solution, to increase the amounts of fermentable sugars, which results in higher alcohol yields.
In starch processing for the production of glucose syrups, the a-amylase is added during mixing
and/or liquefaction, to convert liquefied starch into a maltose-rich solution.
3.1.8. Reaction and fate in food
The a-amylase catalyses the hydrolysis of a1,4-glycosidic linkages in starch (amylose and
amylopectin), glycogen and related polysaccharides and oligosaccharides, resulting in the generation of
soluble dextrins and other oligosaccharides.
Experimental data have been provided on the significant removal (> 99%) of protein in the course
of distilled alcohol production and starch processing for the production of glucose syrups
(Documentation provided to EFSA No 4). The Panel considered this evidence as sufficient to conclude
that the residual amounts of TOS (including substances other than proteins) are removed by
distillation. In addition, when taking into account the purification steps applied to the production of
glucose syrups, i.e. filtration, ion exchange chromatography, treatment with active carbon, the
Panel also considered that the amount of TOS (including the substances other than proteins) in the
final glucose syrup is removed to a similar degree.
3.2. Dietary exposure
As residual amounts of TOS are removed by distillation and by the purification steps applied during
the production of glucose syrups (by > 99%), a dietary exposure was not calculated.
3.3. Toxicological data
The Panel considers the production strain to be of no concern on the basis of the reasons stated in
Section 3.1.4.5. Moreover, taking into account the intended uses, the exposure is negligible (see
Section 3.1.8). Taking this together, the toxicological tests are not needed for the assessment of this
food enzyme.
The applicant provided a bacterial gene mutation assay (Ames test), and an in vitro mammalian
chromosomal aberration test performed with the food enzyme under assessment (batch 4, Table 1).
The applicant also provided a repeated dose 90-day oral toxicity study, which has been performed with
an a-amylase produced with the derivate of an intermediate upstream strain in the same strain lineage
as the strain NZYM-AN (batch 5, Table 1). Despite the view of the Panel that no toxicological tests are
needed, the genotoxicity tests were considered as supporting evidence. The repeated dose 90-day oral
toxicity study was not considered, as it could not be ascertained that the test item was fully
representative of the food enzyme under assessment; however, it is reported in the opinion for
completeness.
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3.3.1. Genotoxicity
3.3.1.1. Bacterial Reverse Mutation test
A bacterial reverse mutation assay was performed according to OECD Test Guideline 471 (OECD,
1997) and following Good Laboratory Practice (GLP) in four strains of Salmonella Typhimurium (TA
1535, TA 1537, TA 98 and TA 100) and Escherichia coli WP2uvrA pKM 101, in the presence or absence
of metabolic activation (S9-mix) applying a ‘treat and plate’ assay. Two experiments were carried out
using six different concentrations (91, 181, 363, 725, 1,450 and 2,900 lg TOS/mL) of the food
enzyme, using appropriate positive controls and deionised water as a negative control. All positive
controls showed a distinct increase of induced revertant colonies, confirming the sensitivity of the tests
and the efficacy of the S9-mix, while the negative control was within the normal ranges. Upon
treatment with the food enzyme, there was no evidence of mutagenic activity at any concentration of
the food enzyme in this mutation test. Therefore, the Panel concluded that the food enzyme did not
induce gene mutations under the conditions employed.
3.3.1.2. In vitro mammalian cell micronucleus test
The in vitro micronucleus assay was carried out according to the OECD Test Guideline 487 (OECD,
2010) and following GLP. Human peripheral whole blood cultures obtained from two female donors
were exposed to the food enzyme for a short treatment (3 + 21 h) in the presence and absence of
S9-mix and a continuous treatment (24 + 24 h) without S9-mix. Proliferation of lymphocytes was
stimulated by addition of phytohaemagglutinin to the cultures. The final concentrations scored for
micronuclei in this study were 1,000, 2,000 and 3,000 lg TOS/mL in the short-term experiments, as
well as 150, 300, 1,000 and 3,000 lg TOS/ml in the long-term treatment experiment. Sterile purified
water was used as a solvent, and appropriate positive controls were included. All positive controls
induced a statistically significant increase of micronucleus frequency and the system was considered
sensitive and valid. Two thousand cells were scored per concentration. In the absence of metabolic
activation, highest cytotoxicity based on replication index reduction was 48% after continuous
(24 + 24 h) treatment with 3,000 lg TOS/mL. Significant increases in the micronucleated binuclear
(MNBN) cell frequency were observed at 1,000 lg TOS/ml following 3 + 21 h treatment with S9-mix
(p ≤ 0.05) and 24 + 24 h treatment without S9-mix (p ≤ 0.01). However, these effects were not
concentration-dependent, not reproducible and fell in the range of historical negative control values.
Therefore, they are not considered to be biologically relevant. Treatment of the cells with the test
substance resulted in frequencies of MNBN cells, which were similar to and not significantly higher
than those observed in concurrent vehicle controls for all the other concentrations analyzed. The
Panel concluded that the food enzyme a-amylase did not induce micronuclei in cultured human
peripheral blood lymphocytes when tested up to 3,000 lg TOS/mL in the test conditions employed.
3.3.2. Repeated dose 90-day oral toxicity study in rodents
A repeated dose 90-day oral toxicity study was performed according to OECD test guideline 408
(OECD, 1998), and following GLP. Groups of 10 male and 10 female Sprague–Dawley rats received the
food enzyme orally via gavage for 90 days at dose levels of 10%, 33% and 100% food enzyme/kg
body weight (bw) per day, adjusted where appropriate with water to dose volumes of 10 mL/kg bw
per day, corresponding to 119, 392 and 1,189 mg TOS/kg bw per day (referred to as low-, mid- and
high-dose groups respectively). A control group received the tap water alone.
No mortality attributed to intake of the food enzyme was observed. No effects on clinical signs,
neurobehavioral changes, body weight, food consumption, ophthalmoscopy, organ weight,
macroscopic and microscopic changes were observed that were considered of toxicological relevance.
Statistically significantly lower total water consumption over the study was observed for high-dose
males compared to control animals. The finding was considered incidental, as it was only observed in
one sex with no dose-relationship.
In mid-dose males, a statistically significantly higher percentage of reticulocytes was observed
compared to the control animals before termination of treatment. This was mainly due to a single
animal showing a high value and considered to be incidental. In mid-dose males, a statistically
significantly lower plasma glucose level was observed before termination of treatment compared to the
control animals. Since no dose-dependency was observed and since the data was within historical
control data and only observed in one sex, it was considered not to be of toxicological importance.
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In mid- and high-dose females, a statistically significantly lower plasma potassium level was
observed before termination of treatment compared to the control animals. However, the values were
not dose related and within historical control data and were considered not to be of toxicological
importance.
The Panel concluded that under the conditions of this repeated dose 90-day oral toxicity study the
no observed adverse effect level (NOAEL) was the highest dose tested, which corresponds to
1,189 mg TOS/kg bw per day.
3.4. Allergenicity
The allergenicity assessment considers only the food enzyme and not any carrier or other excipient,
which may be used in the final formulation.
The potential allergenicity of the a-amylase produced with the genetically modified strain
B. licheniformis NZYM-AN was assessed by comparison of its amino acid sequence with those of
known allergens according to the scientific opinion on the assessment of allergenicity of GM plants and
microorganisms and derived food and feed of the Scientific Panel on Genetically Modified Organisms
(EFSA GMO Panel, 2010). Using higher than 35% identity in a window of 80 amino acids as the
criterion, no match was found.
Limited information is available on occupational respiratory sensitisation to some bacterial
a-amylases (Little and Dolovich, 1973; Vanhanen et al., 1997). Fungal a-amylase from
Aspergillus oryzae is recognised as an occupational respiratory allergen resulting in Baker’s asthma
(Brisman and Belin, 1991; Sander et al., 1998; Brisman, 2002; Quirce et al., 2002). Despite the wide
use of a-amylases, only a low number of case reports of allergic reactions upon oral exposure to
a-amylase in individuals sensitised by inhalation to alpha-amylase have been described (Losada et al.,
1992; Quirce et al., 1992; Baur and Czuppon, 1995; Kanny and Moneret-Vautrin, 1995; Moreno-Ancillo
et al., 2004). Moreover, several studies have shown that adults suffering from occupational asthma
due to enzymes used in food (like a-amylase from A. oryzae) may be able to ingest the corresponding
enzyme without acquiring clinical symptoms of food allergy (Cullinan et al, 1997; Poulsen, 2004;
Armentia et al., 2009).
No oral sensitisation and elicitation reactions to the bacterial a-amylase under evaluation have been
reported.
The Panel noted that an allergic reaction upon oral ingestion of this a-amylase, produced by the
genetically modified B. licheniformis strain NZYM-AN, in individuals sensitised to a-amylase cannot be
excluded, but the likelihood of such reaction to occur is considered to be low.
The applicant provided a study by Bindslev-Jensen et al. (2006) who investigated the possible cross
reactivity of 19 different commercial food enzymes in allergic patients (400 patients allergic to
inhalation allergens, food allergens, allergens of bee or wasp). From the three a-amylases tested of
different B. licheniformis organisms, none was positive in the skin prick test (SPT) or histamine release
test. However, as a flare was seen in the area of the wheal in one patient, the SPT was retested with
that a-amylase in this patient and found to be negative again. Moreover, this a-amylase was further
tested by ingestion (DBPCFC) and found to be negative to both active and placebo challenges. Despite
the fact that no allergic reactions have been observed in these individuals, no conclusion can be drawn
regarding the enzyme under assessment, since the amino acid sequences of the allergens to which the
patients were sensitised are not known.
According to the information provided, substances or products that may cause allergies or
intolerances (Regulation (EU) No 1169/20116) are used as raw materials in the growth
medium of the production organisms. However, during the fermentation process, these products will
be degraded and utilised by the bacteria for cell growth, cell maintenance and production of enzyme
protein. In addition, the bacterial biomass and fermentation solids are removed. Taking into account
the fermentation process and downstream processing, the Panel considered that potentially allergenic
residues of these foods employed as protein sources are not expected to be present.
Quantifying the risk for allergenicity is not possible in view of the individual susceptibility to food
allergens. Allergenicity can be ruled out only if the proteins are fully removed (e.g. in distilled alcohol
6 Regulation (EU) No 1169/2011 of the European Parliament and of the Council of 25 October 2011 on the provision of food
information to consumers, amending Regulations (EC) No 1924/2006 and (EC) No 1925/2006 of the European Parliament and of
the Council, and repealing Commission Directive 87/250/EEC, Council Directive 90/496/EEC, Commission Directive 1999/10/EC,
Directive 2000/13/EC of the European Parliament and of the Council, Commission Directives 2002/67/EC and 2008/5/EC and
Commission Regulation (EC) No 608/2004.
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production). In the starch processing for the production of glucose syrups, although experimental data
showed a significant removal (> 99%) of protein, trace amounts of protein, estimated to be up to
0.5 mg/kg, could be present in glucose syrup. Products, such as candy and ice creams, can contain
about 50% and 40% glucose syrup, respectively, and therefore, proteins could be present in a
quantity sufficient to elicit an allergic reaction.
The Panel considers that under the intended conditions of use the risk of allergic sensitisation and
elicitation reactions upon dietary exposure to this food enzyme cannot be excluded but the likelihood
of such reactions to occur is considered to be low.
Conclusions
Based on the microbial source, the genetic modifications, the manufacturing process, the
compositional and biochemical data, the removal of TOS during the intended food production
processes and the findings in the genotoxicity studies, the Panel concluded that the food enzyme
a-amylase produced with the genetically modified B. licheniformis strain NZYM-AN does not give rise to
safety concerns under the intended conditions of use.
Regarding the allergenicity assessment, the risk of allergic sensitisation and elicitation reactions
upon dietary exposure to this food enzyme cannot be excluded, but the likelihood of such reactions to
occur can be considered to be low.
Documentation provided to EFSA
1) Dossier ‘Application for authorisation of a-amylase produced by a genetically modified strain
of Bacillus licheniformis (strain NZYM-AN)’. September 2014. Submitted by Novozymes A/S.
2) Summary report on genotoxicity and subchronic toxicity study related to alpha-amylase
produced with a strain of Bacillus licheniformis (strain NZYM-AN). March 2015. Delivered by
FoBiG GmbH, Freiburg (Germany).
3) Summary report on GMM part for alpha-amylase produced by Bacillus licheniformis strain
NZYM-AN. June 2015. Delivered by DTU, Copenhagen (Denmark).
4) Additional information on ‘Food enzyme removal during the production of cereal based
distilled alcoholic beverages’ and ‘Food enzyme carry/over in glucose syrups’. February 2017.
Provided by the Association of Manufacturers and Formulators of Enzyme Products.
5) Additional information was received from Novozymes A/S in July 2017.
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Abbreviations
bw body weight
CAS Chemical Abstracts Service
CEF EFSA Panel on Food Contact Materials, Enzymes, Flavourings and Processing Aids
CFU colony forming units
DBPCFC double-blind placebo-controlled food challenge
EC Enzyme Commission
EINECS European Inventory of Existing Commercial Chemical Substances ethylidene-G7pNP
4,6-ethylidene(G7)-p-nitrophenyl(G1)-alpha-D-maltoheptaoside
FAO Food and Agriculture Organization
GLP Good Laboratory Practice
GM genetically modified
GMP Good Manufacturing Practice
HACCP Hazard Analysis and Critical Control Points
IUBMB International Union of Biochemistry and Molecular Biology
KNU(T) Kilo a-amylase units (relative to an internal enzyme standard ‘T’)
LOD limit of detection
MNBN micronucleated binucleated
NOAEL no observed adverse effect level
OECD Organisation for Economic Cooperation and Development
PCR polymerase chain reaction
QPS qualified presumption of safety
SDS-PAGE sodium dodecyl sulfate-poly acrylamide gel electrophoresis
SPT skin prick test
TOS total organic solids
WHO World Health Organization
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